Evaluation of selenium status and effectiveness of selenolin in the treatment of selenium-dependent hepatopathies

The article is devoted to the study of assessment selenium status in pathogenesis liver diseases and effectiveness use a selenium-containing drug. In course studies animals with clinical signs high rates hepatopathies markers – transaminases, 100% cases low level was revealed 0.026 ±0.01 μg / ml, because increased consumption this microelement on background free radical oxidation processes tissue. It found that intramuscular administration drug selenolin at dose 20 mg 100 kg four times an interval 15 days significantly improved experimental animals; therapy 93.3%. Parenteral favorably corrected lipid peroxidation contributed significant (p <0.01) decrease indicator enzymes comparison control by 34.5% (aspartate aminotransferase) 45.8% (alanine aminotransferase), also increase physiological norm (0.068 ± 0.03 ml).